Format

Send to

Choose Destination
Transfus Med. 2015 Dec;25(6):418-23. doi: 10.1111/tme.12219. Epub 2015 Jun 26.

Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.

Author information

1
NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK.
2
Department of Haematology, Oxford University Hospitals, Oxford, UK.
3
Department of Virology, University Hospitals Birmingham, Birmingham, UK.
4
Department of Clinical Haematology, University Hospitals Birmingham, Birmingham, UK.

Abstract

OBJECTIVES:

To establish rates of cytomegalovirus (CMV) transmission with use of CMV-unselected (CMV-U), leukocyte-reduced blood components transfused to CMV-seronegative patient/CMV-seronegative donor (CMV neg/neg) allogeneic stem cell transplantation (SCT) recipients including those receiving T-depleted grafts.

BACKGROUND:

CMV infection remains a major cause of morbidity following SCT. CMV-seronegative SCT recipients are particularly at risk of transfusion transmitted CMV (TT-CMV) and until recently they have received blood components from CMV-seronegative donors with significant resource implications. Although leukocyte reduction of blood components is reported to minimise risk of TT-CMV, its efficacy in high-risk situations, such as in T-depleted transplant recipients, is unknown.

METHODS:

We retrospectively analysed the incidence of TT-CMV in CMV neg/neg allogeneic SCT recipients transfused with CMV-U, leukocyte-reduced blood components in two transplantation centres in the UK. Patients were monitored for CMV infection by weekly CMV polymerase chain reaction testing. Leukocyte reduction of blood components was in accordance with current UK standards.

RESULTS:

Among 76 patients, including 59 receiving in vivo T-depletion, no episodes of CMV infection were detected. Patients were transfused with 1442 CMV-unselected, leukocyte-reduced components, equating to 1862 donor exposures.

CONCLUSIONS:

Our findings confirm the safety of leukocyte reduction as a strategy in preventing TT-CMV in high-risk allogeneic SCT recipients.

KEYWORDS:

T-cell depletion; allogeneic stem cell transplant; cytomegalovirus; leukocyte reduction; transfusion

PMID:
26114211
DOI:
10.1111/tme.12219
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center